Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770134 | 0.92 | KIF11 (0.36) | ALDH1A1TSHRNOS1HSD17B10NOS3 | |
| SCHEMBL2052473 | 0.80 | NOS3 (0.32) | ALDH1A1TSHRNOS1HSD17B10NOS3 | |
| SCHEMBL27858991 | 0.75 | PIK3C3 (0.32) | ALDH1A1TSHRNOS1HSD17B10NOS3 | |
| SCHEMBL2050325 | 0.72 | KIF11 (0.40) | ALDH1A1TSHRNOS1HSD17B10NOS3 | |
| SCHEMBL29285276 | 0.71 | DRD3 (0.36) | ALDH1A1TSHRNOS1HSD17B10NOS3 | |
| SCHEMBL27766777 | 0.71 | KIF11 (0.37) | ALDH1A1TSHRHSD17B10NOS3NOS2 | |
| SCHEMBL12482758 | 0.71 | MAPK1 (0.36) | ALDH1A1TSHRNOS1HSD17B10NOS3 | |
| SCHEMBL498175 | 0.70 | — | — | |
| SCHEMBL28089091 | 0.70 | — | — | |
| SCHEMBL28860098 | 0.69 | DRD4 (0.34) | ALDH1A1NOS3NOS2KIF11POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713319-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024236528-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-11-21 | — | — | WO | disclosed |
| US-11884661-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2022173795-A1 | OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-3538525-B1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-110167935-B | 3-substituted propionic acids as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3590942-B1 | HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-11008331-B2 | Hepatitis B virus surface antigen inhibitor | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2021-05-18 | — | — | US | disclosed |
| US-20200039995-A1 | HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2020-02-06 | — | — | US | disclosed |
| US-10479771-B2 | Pyridazinone and pyridone compounds | BIOTIE THERAPIES CORPORATION (FI) | 2019-11-19 | — | — | US | disclosed |
| US-20100130446-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAS COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2149550-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-7189851-B2 | Condensed heterocyclic compounds as calcitonin agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050107419-A1 | Condensed heterocyclic compounds as calcitonin agonists | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| WO-2003076440-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-18 | — | — | WO | disclosed |
| US-5604224-A | NEURODEGENERATIVE DISORDERS | STERLING WINTHROP INC. (US) | 1997-02-18 | — | — | US | disclosed |
| US-5569655-A | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1996-10-29 | — | — | US | disclosed |
| EP-0647641-A1 | Substituted heterocyclylisoquinolinium salts and compositions and methods of usethereof | STERLING WINTHROP INC. (US) | 1995-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039995-A1 | HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR | HAVCR2, CD74, HLA-B | ALDH1A1 110/4885TSHR 4080/4885NOS1 1890/4885 |
| US-11884661-B2 | 3-substituted propionic acids as αV integrin inhibitors | ITGB3, ITGB1, ITGAV | ALDH1A1 504/4885TSHR 1975/4885NOS1 3766/4885 |
| US-20050107419-A1 | Condensed heterocyclic compounds as calcitonin agonists | CALCRL, CALCR, CALCB | ALDH1A1 4200/4885TSHR 217/4885NOS1 2108/4885 |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | ALDH1A1 889/4885TSHR 592/4885NOS1 1168/4885 |
| US-20100130446-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | GCKR, GCK, SLC5A1 | ALDH1A1 842/4885TSHR 4192/4885NOS1 25/4885 |
| US-10479771-B2 | Pyridazinone and pyridone compounds | XDH, PNPO, PDXK | ALDH1A1 259/4885TSHR 1358/4885NOS1 1466/4885 |
| US-11008331-B2 | Hepatitis B virus surface antigen inhibitor | HAVCR2, CD74, HLA-B | ALDH1A1 110/4885TSHR 4080/4885NOS1 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.